Fukuda opens UK base for patient monitor sales:
This article was originally published in Clinica
Executive Summary
Fukuda Denshi, which claims to have 60% of the Japanese ECG market, has opened a UK office, initially to sell its patient monitoring devices. ECG and ultrasound sales will continue to be handled by its distributor, Cardiacare. Fukuda opened its first European office in 1993. It also has manufacturing plant in the US. In Japan, Fukuda's product line includes pacemakers and ventilators. In the year to March 31, Fukuda Denshi declared group net profits of ¥.62 billion on sales of Yen60.9 billion ($471 million) according to Reuters.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.